Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant plus everolimus versus exemestane plus everolimus in ER-positive, HER2-negative advanced or metastatic breast cancer
2022-000199-20Phase 3Active
- Sponsor
- Genentech
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Giredestrant plus everolimus with Exemestane plus everolimus (2 arms). Primary endpoint: Progression-free survival. Started Jun 2022; status: active.
02
Drugs
giredestranteverolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-000199-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000199-20.